Beta Bionics Inc
BBNXBuild a strategy around BBNX
Beta Bionics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Gross profit TTM grew 70% YoY vs industry median 9% - commercial traction accelerating despite -77.8M net loss[Gross Profit 1Y Growth]
- R&D at 38% of revenue (33.9M TTM) vs 12% industry median - heavy investment phase with 245M working capital runway[Research and Development]
- P/S of 14.3x vs industry median 1.9x - priced for 7x revenue growth that hasn't materialized yet[P/S Ratio]
Watch Triggers
- Total Revenue TTM: Quarterly revenue run-rate exceeds 30M (120M annualized) — Validates commercial scaling thesis; below 25M signals adoption stall
- Operating Expense TTM: Opex grows faster than revenue for 2+ quarters — Would accelerate cash burn and force dilutive financing
- Cash and Equivalents: Falls below 100M (cash + marketable securities) — Would trigger capital raise discussions, likely dilutive
Bull Case
Gross margin 55% TTM at industry median despite early stage - unit economics proven. At 200M revenue, could reach breakeven with current cost structure.
Balance sheet fortress: 295M equity, 0.03 debt/equity, 245M working capital provides runway through 2028+ without dilution at current burn.
Bear Case
Operating margin -77% TTM with 117M opex on 89M revenue - needs 2.5x revenue growth just to cover current costs. No clear path to profitability.
P/S 14.3x vs 1.9x median demands perfection. FCF burn -60.5M TTM means 4-5 years to profitability already priced in with zero margin for error.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage BBNX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Revenue inflection to 150M+ by FY2026 as insulin pump adoption scales
- 70% gross profit growth shows demand exists
- Gross margin 55% enables path to profitability at scale
- 245M working capital funds 4+ years at current burn
Valuation Context
Caveats
Public Strategies Rankings
See how Beta Bionics Inc ranks across different investment strategies.
Leverage BBNX's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
BBNX Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$439.25M | — | ||
$414.98M | — | ||
0.00 | — | ||
$100.25M | +53.9% | — | |
$-1.81 | — | ||
-71.5% | -2.0% | — | |
-73.0% | +11.1% | — | |
$-56.22M | — | ||
-347% | — | ||
Beta 5Y (Monthly) | unknown | — |
BBNX Dividend History
BBNX Stock Splits
BBNX SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
02/24/26 | 12/31/25 | 10-K | |
10/28/25 | 09/30/25 | 10-Q | |
07/29/25 | 06/30/25 | 10-Q | |
05/06/25 | 03/31/25 | 10-Q | |
03/25/25 | 12/31/24 | 10-K | |
01/31/25 | 09/30/24 | 424B4 | |
07/29/25 | 06/30/24 | 10-Q | |
05/06/25 | 03/31/24 | 10-Q | |
01/31/25 | 12/31/23 | 424B4 |